Linked Life Data

21277408

Source:http://linkedlifedata.com/resource/pubmed/id/21277408

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2011-2-28
pubmed:abstractText
Clinical development of malaria vaccines progresses from trials in malaria naïve adults to malaria exposed adults followed by malaria exposed children. It is not well known whether immune responses in non-target populations are predictive of those in target populations, particularly in African children. Therefore humoral responses in three different populations (U.S. adults, Malian adults and Malian children) were compared in this study. They were immunized with 80 ?g of Apical Membrane Antigen 1 (AMA1)/alhydrogel on days 0 and 28. Sera were collected on days 0 and 42; antibody levels were determined by ELISA and the functionality of antibodies was evaluated by Growth Inhibition Assay. After immunization, there was no significant difference in antibody levels between the Malian children and the Malian adults, but U.S. adults showed lower antibody levels. Vaccination did not significantly change growth-inhibitory activity in Malian adults, but inhibition increased significantly in both U.S. adults and Malian children. Vaccine-induced inhibitory activity was reversed by pre-incubation with AMA1 protein, but pre-existing infection-induced inhibition was not. This study shows that humoral responses elicited by the AMA1 vaccine varied depending on the population, most likely reflecting different levels of previous malaria exposure. Thus predicting immune responses from non-target populations is not desirable.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1873-2518
pubmed:author
pubmed:copyrightInfo
Copyright © 2011 Elsevier Ltd. All rights reserved.
pubmed:issnType
Electronic
pubmed:day
9
pubmed:volume
29
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2255-61
pubmed:meshHeading
pubmed-meshheading:21277408-Adolescent, pubmed-meshheading:21277408-Adult, pubmed-meshheading:21277408-Antibodies, Protozoan, pubmed-meshheading:21277408-Antigens, Protozoan, pubmed-meshheading:21277408-Child, Preschool, pubmed-meshheading:21277408-Clinical Trials as Topic, pubmed-meshheading:21277408-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:21277408-Humans, pubmed-meshheading:21277408-Immunity, Humoral, pubmed-meshheading:21277408-Infant, pubmed-meshheading:21277408-Malaria, Falciparum, pubmed-meshheading:21277408-Malaria Vaccines, pubmed-meshheading:21277408-Mali, pubmed-meshheading:21277408-Membrane Proteins, pubmed-meshheading:21277408-Middle Aged, pubmed-meshheading:21277408-Plasmodium falciparum, pubmed-meshheading:21277408-Protozoan Proteins, pubmed-meshheading:21277408-United States, pubmed-meshheading:21277408-Young Adult
pubmed:year
2011
pubmed:articleTitle
Immunological responses against Plasmodium falciparum Apical Membrane Antigen 1 vaccines vary depending on the population immunized.
pubmed:affiliation
Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA. kmiura@niaid.nih.gov
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Intramural